Drug
Surufatinib
Surufatinib: highest development phase Phase 3, developed by Hutchmed, United Therapeutics. 4 trial records tracked on RxWires.
- Highest phase
- Phase 3
- Developer
- Hutchmed, United Therapeutics
Trials
| Drug | Phase | Indication |
|---|---|---|
| Surufatinib NCT02588170 | Phase 3 | Neuroendocrine Tumors |
| Surufatinib NCT02589821 | Phase 3 | Neuroendocrine Tumors |
| surufatinib NCT02549937 | Phase 1/2 | Tumors |
| surufatinib NCT04372394 | Phase 1 | Healthy |
Latest
No recent events.
Follow Surufatinib on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.